With the aim of investing and developing products out of stem cell based platforms in both the therapeutic and non-therapeutic areas, Hyderabad-based healthcare start-up Transcell Biologics has raised an undisclosed amount with Indian Angel Network (IAN) investor Sanjay Jesrani and Nagendra Bandaru leading the round.
Started in 2009, Transcell Biologistics focuses on developing innovative and transformative stem cell based products portfolio.
Dr. Subhadra Dravida, Founder & CEO at Transcell Biologics, said, “IAN has been very encouraging in this journey with aligned business vision in this domain, and we are thankful to them for believing in our passion, capabilities in making a positive impact on the end users, of the discoveries in modern medicine.”
Stem cell therapy is integrated globally to treat many chronic and incurable Diseases such as blood cancers, GVHD, Thalassemia, etc. According to a research of Axis, this bio- banking market is expected to be worth $67 billion in 2017, and Vision gain predicts the world market for biobanking in human medicine will generate $24.4 billion by 2017.
Jesrani, who will be joining the board of the company on behalf of IAN, said, “Last few years we have seen Stem cells related banking and clinical research becoming quite popular worldwide. With the advancement in technology, newer players are entering the Indian market with an aim to not just to preserve precious lives of the coming generation but also for the Regenerative medicine space.”
He added, “Transcell Biologics is one such company who wants to help the needy patient population with the support of their homegrown technologies translations. The company has phenomenal amount of research assets in this domain, and we believe they will continue to excel in the industry to be a market leader.”
